Peptide-conjugate antisense based splice-correction for Duchenne muscular dystrophy and other neuromuscular diseases.
Tsoumpra MK, Fukumoto S, Matsumoto T, Takeda S, Wood MJA, Aoki Y. EBioMedicine. 2019 Jul;45:630-645. doi: 10.1016/j.ebiom.2019.06.036. Epub 2019 Jun 27.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6642283/
Clinical Pharmacology Studies Supporting Oligonucleotide Therapy Development: An Assessment of Therapies Approved and in Development Between 2012-2018.
Rogers H, Adeniyi O, Ramamoorthy A, Bailey S, Pacanowski M.
Clin Transl Sci. 2020 Dec 5. doi: 10.1111/cts.12945. Online ahead of print.
https://ascpt.onlinelibrary.wiley.com/doi/10.1111/cts.12945
Bergsma AJ, in ’t Groen SLM, Catalano F, Yamanaka M, Takahashi S, Okumiya T, van der Ploeg AT, Pijnappel WWMP. A generic assay for the identification of splicing variants that induce nonsense-mediated decay in Pompe disease. Eur J Hum Genet. 2020;{Epub ahead of print]. doi:10.1038/s41431-020-00751-3
https://www.nature.com/articles/s41431-020-00751-3
Genetic compensation prevents myopathy and heart failure in an in vivo model of Bag3 deficiency.
Diofano F, Weinmann K, Schneider I, Thiessen KD, Rottbauer W, Just S.
PLoS Genet. 2020 Nov 2;16(11):e1009088. doi: 10.1371/journal.pgen.1009088. eCollection 2020 Nov.
https://journals.plos.org/plosgenetics/article?id=10.1371/journal.pgen.1...
Rosenke K, Leventhal S, Moulton H, Hatlevig S, Hawman D, Feldmann H, Stein DA. Inhibition of SARS-CoV-2 in Vero cell cultures by peptide-conjugated morpholino-oligomers. J Antimicrob Chemother. 2020;[Epub ahead of print]:dkaa460 doi:10.1093/jac/dkaa460.
https://academic.oup.com/jac/advance-article/doi/10.1093/jac/dkaa460/596...
Rosenke K, Leventhal S, Moulton H, Hatlevig S, Hawman D, Feldmann H, Stein DA. Inhibition of SARS-CoV-2 in Vero cell cultures by peptide-conjugated morpholino-oligomers. bioRxiv. 2020;[preprint] doi:10.1101/2020.09.29.319731.
https://www.biorxiv.org/content/10.1101/2020.09.29.319731v1
Here's a broad review of the RNA therapeutics field, hosted on two sites.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7495341/
https://pharmrev.aspetjournals.org/content/72/4/862
Another specificity control strategy involving mutants and Morpholinos
Cunningham CM, Bellipanni G, Habas R, Balciunas D. Deletion of morpholino binding sites (DeMOBS) to assess specificity of morphant phenotypes. Sci Rep. 2020 Sep 21;10(1):15366. doi: 10.1038/s41598-020-71708-1.
https://www.nature.com/articles/s41598-020-71708-1
Marchalot A, Lambert J-M, Boyer F, Pollet J, Moreau J, Feuillard J, Faumont N, Delpy L. Splice switching oligonucleotide mediated gene knockdown in B cells and plasma cells. bioRxiv. 2020;[preprint] doi:10.1101/2020.09.18.302984
https://www.biorxiv.org/content/10.1101/2020.09.18.302984v1
Links to resources for designing splice-switching oligos
On the mechanism behind many differing phenotypes of morphants and mutants.
Sztal TE, Stainier DYR. Transcriptional adaptation: a mechanism underlying genetic robustness. Development. 2020 Aug 14;147(15):dev186452. doi: 10.1242/dev.186452.
https://dev.biologists.org/content/147/15/dev186452
This paper presents an example of a Morpholino off-target effect shown by testing the Morpholino in a CRISPR mutants.
Jiang Z, Carlantoni C, Allanki S, Ebersberger I, Stainier DYR. Tek/Tie2 is not required for cardiovascular development in zebrafish. Development. 2020 Sep 14:dev.193029. doi: 10.1242/dev.193029. Online ahead of print.
https://dev.biologists.org/content/early/2020/09/12/dev.193029
